

Summary of minutes of EUCAST Steering Committee Meeting Vienna, Austria, 15-16 February 2011

Attending

Dr Petra Apfalter	PA	EUCAST	Austria
Dr Derek F.J. Brown	DB	Scientific Secretary	United Kingdom
Dr Rafael Cantón	RC	Clinical Data Co-ordinator	Spain
Dr Christian Giske	CG	SRGA	Sweden
Dr Marina Ivanova	MI	EUCAST	Estonia
Prof Gunnar Kahlmeter	GK	Chairperson	Sweden
Prof Alasdair P. MacGowan	AM	BSAC	United Kingdom
Dr Johan W. Mouton	JM	CRG	The Netherlands
Prof Arne Rodloff	AR	DIN	Germany
Prof Claude-James Soussy	CS	CA-SFM	France
Dr Martin Steinbakk	MS	NWGA	Norway

Present for item 21 and 22

Dr Robert Skov	State Serum Institute	Denmark
----------------	-----------------------	---------

1	Chairman's welcome
2	Minutes of meeting of 22-23 November 2010 The minutes were accepted as a correct record.
3	Matters arising from minutes of 22-23 Nov 2010 (items not covered by agenda) A paper for CMI explaining ECOFFs is to be prepared. MIC distributions for <i>C. difficile</i> will be added to the MIC database. Approaches to dealing with the effects of changing breakpoints on resistance surveillance have been sent to ECDC. Cefotaxime, cefuroxime, ceftazidime, benzylpenicillin, phenoxymethylpenicillin, piperacillin-tazobactam and amoxicillin documents have been released. ECOFFs have been defined for Enterobacteriaceae.
4	New agents A cephalosporin is about to be submitted to EMA.
5	Status of EUCAST rationale documents The current status of several documents was reviewed and several documents updated.
6	Breakpoint issues ECOFFs will be established for moxifloxacin and levofloxacin with viridians streptococci. A policy will be established for dealing with breakpoints for agent-organism combinations for which there is no EMA license.
7	Expert rules subcommittee Publication of version 2 is expected soon, together with expert rules software.
8	Antifungal susceptibility testing subcommittee Proposed breakpoints and rationale documents for posaconazole, anidulafungin and amphotericin B will be released for consultation.
9	Anaerobe subcommittee No new information.
10	Organisms without EUCAST breakpoints Discussions with the EMGM on <i>N. meningitidis</i> breakpoints are continuing. Proposed breakpoints for <i>H. pylori</i> , with notes, will be released for consultation with all groups. ECOFFs for <i>C. difficile</i> will be released.

The status of breakpoints and current projects for several other groups was reviewed.

- 11 ECCMID Milan 8-10 May, 2011** There will be several EUCAST sessions.
- 12 EMA** EUCAST comments on the draft document “Guideline on the Evaluation of Medicinal Products indicated for Treatment of Bacterial Infections” will be sent to EMA.
- 13 CLSI** GK and DB reported on several useful sessions at the January 2011 meeting in Orlando.
- 14 ECDC** The next tender period will run from September 2011. There will be changes to the grant periods to bring the funding periods into line with ECDC funding streams.
- 15 Implementation of EUCAST breakpoints** GK and DB presented maps showing implementation of NACs, EUCAST breakpoints and EUCAST disk diffusion in Europe. There has been rapid progress in implementation.
- Manufacturers’ readiness for EUCAST breakpoints and methods continues to be an issue with some details but there is constant progress.
- Breakpoint tables continue to be developed and extended.
- Moraxella catarrhalis* breakpoints will be released for general consultation.
- Noted that a *N. gonorrhoeae* QC control strain is needed.
- 16 EUCAST statutes** An updated version will be presented for ratification at the General Committee meeting at ECCMID.
- 17 Website** The frequently asked questions section continues to be expanded. An errata section has been added to cover typographical errors to be corrected in the next version. A section listing changes to the website has been added to the homepage and there is a section giving previous versions of tables. A note on update of documents was approved.
- 18 Co-amoxiclav breakpoints and susceptibility testing** Discussions continue on the most appropriate fixed concentration of clavulanate.
- 19 Cefixime and *N. gonorrhoeae*** Propose reduction of the breakpoints to 0.06/0.06 mg/L will be sent this to national committees for consultation.
- 20 Trimethoprim-sulfametrol** Susceptibility of all trimethoprim-sulfonamide combinations can be inferred from the trimethoprim-sulfamethoxazole susceptibility.
- 21 Ciprofloxacin breakpoints for *Salmonella* spp.** Separate breakpoint will be provided.
- 22 Testing *S. aureus* for β -lactamase production** Use of sharp edge/cloverleaf tests were discussed following a presentation by RS.
- 23 Detection of β -lactam resistance in *H. influenzae*** Detection of β -lactam resistance in *H. influenzae* was discussed.
- 24 Beta-lactamase inhibitor combination** There was a preliminary presentation from a manufacturer.
- 25 Any other business** None.
- 26 Next meetings** 10-11 May 2011, Milan, Italy (after ECCMID).
11-12 July 2011, Stockholm, Sweden; 26-27 September 2011, Berlin, Germany; 21-22 November 2011, Brussels, Belgium; 30-31 January 2012, Paris, France; 3-4 April 2012, London, UK.

Ratified summary of minutes of meeting 15-16 February 2011. Prepared by DB, GK and RC